View Financial HealthSOHM 배당 및 자사주 매입배당 기준 점검 0/6SOHM 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.공시 • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.공시 • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.공시 • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.공시 • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.공시 • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 SHMN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: SHMN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장SOHM 배당 수익률 vs 시장SHMN의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SHMN)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (SHMN) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SHMN 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SHMN 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SHMN 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: SHMN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 20:37종가2026/05/22 00:00수익2012/12/31연간 수익2012/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스SOHM, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.
공시 • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.
공시 • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.
공시 • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.
공시 • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.
공시 • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.